Effectiveness of pentoxyfylline in patients with fatty liver
- Conditions
- onalcoholic steatohepatitis
- Registration Number
- SLCTR/2014/016
- Lead Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
1. Ultrasonographic evidence of fatty liver
2. Nonalcoholic fatty liver disease activity score greater than or equal to 5 on liver histopathology
1. Significant alcohol intake(more than 20 gm /day)
2. History of taking drugs that may cause fatty liver(i.e.tamoxifen, valproic acid, amiodarone, methotrexate) or history of taking drugs that have shown benefit in previous Nonalcoholic steatohepatitis studies(i.e.vitamin E ,metformin, thiazolidinedione, fibrates)
3. Chronic viral hepatitis(HBV , HCV)
4. Pregnancy
5. Co-morbid conditions(Chronic Obstructive Pulmonary Disease ,Chronic Kidney Disease, Congestive CF, Myocardial infarction)
6. Liver failure
7. Hypothyroidism
8. Patient who fails to give consent for paired biopsy
9. Wilson's disease and Hemochromatosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of nonalcoholic fatty liver disease activity score and fibrosis score after one year treatment [At the end of one year]<br>
- Secondary Outcome Measures
Name Time Method one [None]<br>